Glucagon-like peptide-1 receptor agonists in adults with cystic fibrosis-related diabetes: Rationale and emerging evidence.
作者信息
Assalia Naffa Mai, Ayada Gida, Zolotov Sagit, Shehadeh Naim, Nakhleh Afif
机构信息
Maccabi Healthcare Services, Haifa, Israel.
Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, Haifa, Israel.
出版信息
Diabetes Obes Metab. 2025 Sep;27(9):4621-4626. doi: 10.1111/dom.16516. Epub 2025 Jun 9.
Abstract
摘要
相似文献
1
Glucagon-like peptide-1 receptor agonists in adults with cystic fibrosis-related diabetes: Rationale and emerging evidence.成人囊性纤维化相关糖尿病患者使用胰高血糖素样肽-1受体激动剂：理论依据与新证据
Diabetes Obes Metab. 2025 Sep;27(9):4621-4626. doi: 10.1111/dom.16516. Epub 2025 Jun 9.
2
Preservation of β-cell Function in Pancreatic Insufficient Cystic Fibrosis With Highly Effective CFTR Modulator Therapy.高效 CFTR 调节剂治疗胰腺功能不全囊性纤维化β细胞功能的保存。
J Clin Endocrinol Metab. 2023 Dec 21;109(1):151-160. doi: 10.1210/clinem/dgad443.
3
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.肠降血糖素（GLP-1 受体激动剂和双重/三重激动剂）与肝脏。
J Hepatol. 2023 Dec;79(6):1557-1565. doi: 10.1016/j.jhep.2023.07.033. Epub 2023 Aug 9.
4
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
5
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.胰高血糖素样肽-1受体激动剂对2型糖尿病患者体重减轻的影响：一项系统评价与混合治疗比较的Meta分析
PLoS One. 2015 Jun 29;10(6):e0126769. doi: 10.1371/journal.pone.0126769. eCollection 2015.
6
Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy.囊性纤维化跨膜传导调节因子调节剂对孕期及产后母体结局的影响。
Chest. 2025 Feb;167(2):348-361. doi: 10.1016/j.chest.2024.09.019. Epub 2024 Sep 27.
7
Effects of GLP-1 and GIP on Islet Function in Glucose-Intolerant, Pancreatic-Insufficient Cystic Fibrosis.GLP-1 和 GIP 对葡萄糖耐量受损、胰腺功能不全的囊性纤维化胰岛功能的影响。
Diabetes. 2022 Oct 1;71(10):2153-2165. doi: 10.2337/db22-0399.
8
Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis.囊性纤维化跨膜传导调节因子调节剂及专门的囊性纤维化胃肠道门诊就诊对囊性纤维化患者远端肠梗阻综合征发病率的影响。
PLoS One. 2025 Jul 28;20(7):e0328015. doi: 10.1371/journal.pone.0328015. eCollection 2025.
9
Proinflammatory cytokine-induced alpha cell impairment in human islet microtissues is partially restored by dual incretin receptor agonism.在人胰岛微组织中，促炎细胞因子诱导的α细胞损伤可通过双重肠促胰岛素受体激动作用得到部分恢复。
Diabetologia. 2025 May 15. doi: 10.1007/s00125-025-06425-3.
10
Changes in immunofluorescence staining during islet regeneration in a cystic fibrosis-related diabetes (CFRD) ferret model.囊性纤维化相关糖尿病（CFRD）雪貂模型中胰岛再生过程中免疫荧光染色的变化。
Islets. 2024 Dec 31;16(1):2436696. doi: 10.1080/19382014.2024.2436696. Epub 2024 Dec 6.
本文引用的文献
1
GLP-1-based therapies for diabetes, obesity and beyond.基于胰高血糖素样肽-1（GLP-1）的糖尿病、肥胖症及其他疾病治疗方法。
Nat Rev Drug Discov. 2025 Apr 25. doi: 10.1038/s41573-025-01183-8.
2
Elucidating the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Intolerance in People With Cystic Fibrosis.阐明依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化患者葡萄糖不耐受的影响。
J Clin Endocrinol Metab. 2025 Mar 24. doi: 10.1210/clinem/dgaf165.
3
Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review.胰高血糖素样肽-1受体激动剂治疗合并肥胖的囊性纤维化相关糖尿病：病例系列及文献综述
J Clin Transl Endocrinol. 2024 Nov 7;38:100375. doi: 10.1016/j.jcte.2024.100375. eCollection 2024 Dec.
4
Glycemia and Insulin Secretion in Cystic Fibrosis Two Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO.艾莱克卡福/替扎卡福/依伐卡福治疗两年后囊性纤维化患者的血糖与胰岛素分泌：PROMISE-ENDO研究
J Clin Endocrinol Metab. 2024 Dec 9. doi: 10.1210/clinem/dgae857.
5
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025.9. 血糖治疗的药理学方法：2025年糖尿病护理标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S181-S206. doi: 10.2337/dc25-S009.
6
Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs.囊性纤维化相关性糖尿病与 GLP-1 受体的胰岛蛋白表达减少和细胞特异性转录程序紊乱有关。
Sci Rep. 2024 Oct 28;14(1):25689. doi: 10.1038/s41598-024-76722-1.
7
GLP-1 Receptor Agonist Therapy in Cystic Fibrosis-Related Diabetes: A Case Report.胰高血糖素样肽-1受体激动剂治疗囊性纤维化相关糖尿病：一例报告
Diabetes Technol Ther. 2025 Feb;27(2):144-146. doi: 10.1089/dia.2024.0367. Epub 2024 Oct 3.
8
Cystic Fibrosis-related Diabetes: A First Canadian Clinical Practice Guideline.囊性纤维化相关糖尿病：加拿大首个临床实践指南。
Can J Diabetes. 2025 Feb;49(1):19-28.e16. doi: 10.1016/j.jcjd.2024.09.001. Epub 2024 Sep 12.
9
Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis.胰高血糖素样肽-1激动剂疗法用于成年囊性纤维化患者。
J Cyst Fibros. 2025 Jan;24(1):40-46. doi: 10.1016/j.jcf.2024.08.005. Epub 2024 Aug 30.
10
Cystic fibrosis.囊性纤维化。
Nat Rev Dis Primers. 2024 Aug 8;10(1):53. doi: 10.1038/s41572-024-00538-6.
Zotero 插件